A
Adendra Therapeutics
Adendra is an emerging biotechnology company building on new insights into dendritic cell biology to discover and develop new small molecule and biologic medicines for the treatment of a wide range of…
About Adendra Therapeutics
Adendra Therapeutics is a cutting-edge biotechnology startup focused on developing innovative immunotherapies for treating solid tumors and autoimmune diseases. The company leverages the latest scientific insights into dendritic cell biology to create new treatments that can potentially transform the landscape of cancer and autoimmune disease therapy.
Adendra Therapeutics primarily serves patients suffering from cancer and autoimmune conditions, as well as healthcare providers and research institutions looking for advanced treatment options. The company operates in the highly specialized and competitive biotechnology and life sciences market, which is characterized by rapid innovation and significant investment in research and development.
The business model of Adendra Therapeutics revolves around the discovery and development of novel small molecules and biologic medicines. These are specialized drugs designed to target specific aspects of the immune system, particularly dendritic cells, which play a crucial role in initiating and regulating immune responses. By focusing on these cells, Adendra aims to develop therapies that can more effectively combat diseases with fewer side effects compared to traditional treatments.
Adendra Therapeutics generates revenue through a combination of research grants, partnerships with pharmaceutical companies, and potential future sales of its proprietary therapies. The company may also engage in licensing agreements, where it allows other companies to use its technology in exchange for royalties or upfront payments.
In summary, Adendra Therapeutics is at the forefront of developing next-generation immunotherapies by harnessing the power of dendritic cell biology. The company's innovative approach holds promise for creating more effective treatments for cancer and autoimmune diseases, offering hope to patients and healthcare providers alike.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- North Mymms, United Kingdom
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 56.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, uk is8 life sciences, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Dec 2021 | $53M | $212M | Apple Tree Partners | ↗ |
| SPINOUTOther financing | Jan 2021 | $0 | — | The Francis Crick Institute | — |
Growth signals
Latest recorded traffic for Adendra Therapeutics is 2.7K monthly website visits, up 285.7% over the last three months. Adendra Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
SeniscaRNA senotherapeutics reversing cellular aging for disease treatment |
Exeter, United Kingdom | Operational | 15 | $8.2M | $20M |
SpireaAdvanced antibody-drug conjugate technology for cancer therapeutics |
Harrogate, United Kingdom | Operational | |||
MICA BiosystemsBiomagnetic technology for remote-controlled regenerative medicine applications |
Solihull, United Kingdom | Operational | |||
GelmetixInjectable polymer gel for non-surgical chronic pain treatment |
London, United Kingdom | Operational | |||
RenovosNanoclay gel platform for regenerative medicine therapeutics |
Chilworth, United Kingdom | Operational | |||
FemtogenixDNA-interactive payloads for antibody-drug conjugates |
St Albans, United Kingdom | Operational | |||
Keapstone TherapeuticsSmall molecule activators for neurodegenerative disease therapies |
Sheffield, United Kingdom | Operational | |||
IGEM TherapeuticsImmuno-oncology IgE antibodies for treating solid tumors |
London, United Kingdom | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Adendra Therapeutics in the North Mymms ecosystem
The Adendra Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Apple Tree Partners
Other known investors1 additional known investor
The Francis Crick Institute
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Adendra Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adendra Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









